Regeneron Investors Can't Use FCA Action To Support Suit
By Sydney Price · September 21, 2026, 5:30 PM EDT
Regeneron Pharmaceuticals Inc. and its executives have beaten a proposed class action accusing them of misleading investors about the company's revenue prospects for its vision loss drug and inflating reimbursements, with...
To view the full article, register now.